Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II trial to commence for diabetes vaccine

Aug. 28, 2000

Cysteine and serine protease inhibitors useful for osteoporosis, etc.

Aug. 25, 2000

Novel compound LR-90 shows both hypolipidemic and hypoglycemic activities

Aug. 25, 2000

FDA grants approval for Unithroid as thyroid hormone replacement therapy

Aug. 25, 2000

Compound in cinnamon affects glucose metabolism

Aug. 25, 2000

New nonpeptide glucagon antagonists useful for hyperglycemia, etc.

Aug. 24, 2000

Vivelle receives FDA approval for prevention of osteoporosis

Aug. 23, 2000

Research reveals new gene target for osteoporosis treatment

Aug. 23, 2000

Wyeth-Ayerst recommends that certain lots of Norplant not be implanted

Aug. 22, 2000

Research links development of type 1 diabetes with inflammation

Aug. 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...